The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Addition of peginterferon alpha (PEG‐IFN add‐on) to entecavir (ETV) treatment after a short lead‐in phase results in more response than ETV monotherapy in HBeAg‐positive chronic hepatitis B infection (CHB). This study is the first to assess long‐term efficacy of this treatment strategy. Patients who received ETV ± 24 weeks of PEG‐IFN add‐on in a global trial (ARES study) and completed follow‐up were...
It is unknown whether peginterferon (PEG‐IFN) add‐on to entecavir (ETV) leads to more HBsAg decline compared to PEG‐IFN monotherapy or combination therapy, and whether ETV therapy may prevent HBsAg increase after PEG‐IFN cessation. We performed a post hoc analysis of 396 HBeAg‐positive patients treated for 72 weeks with ETV + 24 weeks PEG‐IFN add‐on from week 24 to 48 (add‐on, n = 85), 72 weeks with...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.